ZTS

Business Profile & Competitive Position

Zoetis Inc. (ticker: ZTS) is classified in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Operationally, it is a global animal-health company focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions.

The company commercializes products across eight core species—dogs, cats, and horses in the companion-animal segment, and cattle, swine, poultry, fish, and sheep in the livestock segment—spread across seven major product categories and sold in more than 100 countries. In 2025, U.S. revenue reached $5,097 million, or 54% of total revenue, while International revenue was $4,254 million, or 45%. Companion animal products represented approximately 70% of revenue, and livestock products represented roughly 29%.

Product concentration is real and worth tracking: in 2025, Simparica and Simparica Trio contributed approximately 16% of revenue, Apoquel and Apoquel Chewable contributed approximately 12%, and the top five product lines together accounted for roughly 42% of revenue. The company also completed the divestiture of its medicated feed additive portfolio, certain water soluble products, and related assets on October 31, 2024.

The margin data support the view that Zoetis carries meaningful competitive positioning. A net margin of 27.5% and a return on equity of 69.3% sit well above what commodity-like health-product businesses typically produce, suggesting durable pricing power, veterinarian and pet-owner loyalty tied to clinical outcomes, and comparatively efficient capital deployment.

Financial Posture

Zoetis currently trades at $73.64, giving it a market capitalization of $30.9 billion and a price-to-earnings ratio of 12.1. Pairing that P/E with a 27.5% net margin and a 69.3% ROE is noteworthy: the market is applying a relatively modest earnings multiple to a business with very high profitability and capital returns.

The stock's beta is 0.73, which is consistent with the lower volatility typically associated with defensive healthcare and animal-health franchises. On a short-term technical snapshot, the RSI is 43.6 and the price sits below the 50-day exponential moving average of $76.78.

Those figures are purely descriptive. They describe where the stock is priced and how it has recently behaved relative to its moving average, but they do not, by themselves, imply any forward direction or recommendation.

Strategic Priorities & Outlook

Zoetis's most recent SEC 10-K filing lays out several concrete operational priorities. The company continues to emphasize the discovery and development of new chemical, biopharmaceutical, and biological entities, alongside product lifecycle innovation. In vaccines, it is pursuing development of new products for emerging infectious diseases under a "first to know and fast to market" operating philosophy.

On the technology side, Zoetis is integrating new AI-driven diagnostic capabilities into its Vetscan Imagyst platform to expand veterinary point-of-care testing. A more administrative but still material 2026 priority is the elimination of the one-month reporting lag for subsidiaries outside the U.S., as well as aligning the fiscal years of subsidiaries within the U.S. and International segments. That change could make quarter-to-quarter revenue recognition cleaner and more directly comparable for investors.

Macro & Geopolitical Exposure

As a global specialty and generic drug manufacturer focused on animal health, Zoetis is exposed to several macro and geopolitical forces. Regulatory risk is central to the industry: changes in FDA policy, foreign regulator approvals, or veterinary prescribing rules can affect product launches, label expansions, and margins.

Because 45% of revenue comes from outside the U.S., currency translation is a meaningful factor. A stronger U.S. dollar reduces the reported value of overseas sales, while a weaker dollar increases it. Livestock demand is also sensitive to agricultural commodity prices, feed costs, and farm-level economics, which influence producer spending on vaccines and treatments.

Trade policy matters as well, affecting both import tariffs on raw materials and export access for finished products. Finally, disease outbreaks among companion animals or livestock can create demand spikes for vaccines but can also disrupt distribution or supply chains in affected regions.

Recent Developments

Recent news flow has focused on institutional positioning rather than operational news. On September 9, 2026, finbold.com reported that Michael Burry had updated his September portfolio, while defenseworld.net noted that HB Wealth Management LLC had boosted its holdings in Zoetis. On September 10, 2026, defenseworld.net published a critical analysis comparing Zoetis (NYSE:ZTS) and Urogen Pharma (NASDAQ:URGN). By September 14, 2026, defenseworld.net reported that Corient Private Wealth LP held $35.07 million in Zoetis stock.

Taken together, these headlines point to continued institutional attention during the September 2026 period. Position disclosures do not, on their own, indicate a directional signal, but they do confirm that asset managers were actively adjusting their Zoetis exposure heading into the next earnings cycle.

Earnings Behavior & Post-Earnings Drift

Zoetis has produced strong headline earnings consistency over the last eight reported quarters, beating the consensus estimate in seven of those eight quarters, for an 88% beat rate, with an average earnings surprise of 3.9%. However, the post-earnings price action has been weaker than the beat rate would suggest. Across those same eight quarters, the average five-day price move after earnings was -4.1%, classified as a negative post-earnings drift.

The disconnect shows up clearly in recent quarters. On August 6, 2026, actual EPS of $1.87 beat the estimate of $1.85 by 1.1%, yet the stock fell 5.97% the next day and drifted down 1.85% over the next five sessions. On February 12, 2026, actual EPS of $1.48 beat the estimate of $1.40 by 5.7%, but the stock only gained 0.8% the next day, though it did rise 2.5% over the following five days. On November 4, 2025, actual EPS of $1.70 beat the estimate of $1.62 by 4.9%, yet the stock dropped 3.19% the next day and 3.49% over the next five sessions.

The dynamic is not symmetrical on misses. The May 7, 2026 report, with actual EPS of $1.53 versus an estimate of $1.60—a -4.4% surprise—led to a 5.13% one-day decline and a 13.55% decline over five days. So beats have not reliably produced follow-through gains, while misses have been punished more decisively. One plausible interpretation is that the market's real expectation runs ahead of the published consensus, or that guidance and management commentary carry at least as much weight as the headline EPS print.

Zoetis is scheduled to report next on November 3, 2026, before the market open, with a consensus EPS estimate of $1.52.

For a deeper dive into how institutional analysts and major funds are collectively positioned on Zoetis, readers should review the full institutional verdict section, which consolidates sell-side ratings, ETF ownership, and other aggregate signals beyond the raw data covered here.